What is Zacks Small Cap’s Forecast for MGRM Q1 Earnings?

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Monogram Orthopaedics in a research report issued on Thursday, March 13th. Zacks Small Cap analyst T. Kerr anticipates that the company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.49) per share. Zacks Small Cap also issued estimates for Monogram Orthopaedics’ Q2 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.16) EPS.

Several other research firms have also weighed in on MGRM. Roth Capital upgraded Monogram Orthopaedics to a “strong-buy” rating in a research report on Monday, December 9th. Roth Mkm started coverage on Monogram Orthopaedics in a research report on Monday, December 9th. They set a “buy” rating and a $4.00 price target on the stock.

Monogram Orthopaedics Stock Performance

Shares of MGRM stock opened at $2.33 on Monday. Monogram Orthopaedics has a fifty-two week low of $1.53 and a fifty-two week high of $4.90. The firm has a market cap of $79.95 million, a P/E ratio of -4.96 and a beta of 1.66. The business’s 50 day moving average price is $2.54 and its 200-day moving average price is $2.49.

Monogram Orthopaedics (NASDAQ:MGRM) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MGRM. Jane Street Group LLC purchased a new position in Monogram Orthopaedics during the fourth quarter valued at $25,000. Wells Fargo & Company MN raised its stake in Monogram Orthopaedics by 286.6% during the fourth quarter. Wells Fargo & Company MN now owns 11,597 shares of the company’s stock valued at $27,000 after buying an additional 8,597 shares during the last quarter. Barclays PLC purchased a new position in Monogram Orthopaedics during the third quarter valued at $29,000. Orion Portfolio Solutions LLC purchased a new position in Monogram Orthopaedics during the fourth quarter valued at $31,000. Finally, State Street Corp purchased a new position in Monogram Orthopaedics during the third quarter valued at $62,000. Hedge funds and other institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.